bioMerieux (OTCMKTS:BMXMF – Get Free Report) has been assigned a consensus rating of “Reduce” from the six brokerages that are covering the stock, Marketbeat.com reports. One investment analyst has rated the stock with a sell rating and five have given a hold rating to the company.
A number of research firms have weighed in on BMXMF. Piper Sandler initiated coverage on bioMerieux in a research report on Thursday, June 11th. They set a “neutral” rating on the stock. Morgan Stanley reissued an “underweight” rating on shares of bioMerieux in a research report on Friday, September 11th. Zacks Research upgraded bioMerieux from a “strong sell” rating to a “hold” rating in a research report on Monday, September 28th. Finally, Deutsche Bank Aktiengesellschaft reaffirmed a “hold” rating on shares of bioMerieux in a research note on Wednesday, June 17th.
Read Our Latest Research Report on BMXMF
bioMerieux Stock Down 0.2%
bioMerieux Company Profile
bioMérieux is a France-based healthcare company specializing in in vitro diagnostics. The company develops, manufactures and markets diagnostic systems, reagents and software used to detect infectious diseases, support antimicrobial therapy decisions and assist with disease management.
Its product portfolio includes solutions for microbiology, molecular biology, immunoassays and syndromic testing. bioMérieux’s systems are used by hospitals, clinical laboratories and healthcare providers, while its industrial applications serve the food, pharmaceutical and cosmetics industries by helping customers monitor contamination, quality and safety.
Founded in 1963 by Alain Mérieux, bioMérieux traces its heritage to the Mérieux family’s work in medical diagnostics.
Featured Stories
- Five stocks we like better than bioMerieux
- NVIDIA’s Record High Raises a Bigger Question About How Far the Rally Can Run
- A Manufacturing Surprise Could Be a Big Win for These 2 Companies
- What a $1 Billion Chip Deal Says About Amazon’s AI Ambitions
- 3 Stocks Benefiting From AI Demand Just Announced Major Buybacks
Receive News & Ratings for bioMerieux Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for bioMerieux and related companies with MarketBeat.com's FREE daily email newsletter.
